5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors-Reference-Cited by-同舟云学术

5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

Published:2005-06 Issue:11 Volume:13 Page:3705-3720
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Matulenko Mark A.,Lee Chih-Hung,Jiang Meiqun,Frey Robin R.,Cowart Marlon D.,Bayburt Erol K.,DiDomenico Stanley,Gfesser Gregory A.,Gomtsyan Arthur,Zheng Guo Zhu,McKie Jeffery A.,Stewart Andrew O.,Yu Haixia,Kohlhaas Kathy L.,Alexander Karen M.,McGaraughty Steve,Wismer Carol T.,Mikusa Joseph,Marsh Kennan C.,Snyder Ronald D.,Diehl Marilyn S.,Kowaluk Elizabeth A.,Jarvis Michael F.,Bhagwat Shripad S.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference59 articles.

1. Purinergic Approaches in Experimental Therapeutics;Williams,1997

2. Purinergic Modulation of Pain

3. Purinergic and pyrimidinergic receptors as potential drug targets

4. Purinergic Approaches in Experimental Therapeutics;Geiger,1997

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and evaluation of novel pyrido fused piperazine derivatives: In vitro cytotoxicity study over various cancer cell lines;Results in Chemistry;2023-12

2. A convergent multicomponent synthesis, spectral analysis, molecular modelling and docking studies of novel 2H-pyrido[1,2-a]pyrimidine-2,4(3H)-dione derivatives as potential anti-cervical cancer agents;Journal of Molecular Structure;2023-05

3. о-Aminopyrimidine Aldehydes and Ketones: Synthesis and use as Precursors to Fused Pyrimidines;Chemistry of Heterocyclic Compounds;2022-11

4. Adenosine kinase (ADK) inhibition with ABT-702 induces ADK protein degradation and a distinct form of sustained cardioprotection;European Journal of Pharmacology;2022-07

5. Adenosine kinase: A key regulator of purinergic physiology;Biochemical Pharmacology;2021-05